Rallybio (NASDAQ:RLYB – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.
Rallybio Stock Performance
NASDAQ:RLYB opened at $0.74 on Monday. The firm has a market capitalization of $30.87 million, a price-to-earnings ratio of -0.46 and a beta of -1.45. Rallybio has a 52-week low of $0.68 and a 52-week high of $3.46. The stock has a fifty day moving average of $0.84 and a 200 day moving average of $0.99.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Rallybio in a research note on Wednesday, February 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Rallybio currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Featured Stories
- Five stocks we like better than Rallybio
- Overbought Stocks Explained: Should You Trade Them?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Invest in the FAANG Stocks
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Should You Invest in Penny Stocks?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
